Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Clinical trial NCT05372614 · RECRUITING

Trial details

NCT number: NCT05372614
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Malignant Solid Neoplasm Metastatic Pancreatic Adenocarcinoma Stage III Pancreatic Cancer AJCC v8 Stage IV Pancreatic Cancer AJCC v8 Unresectable Malignant Solid Neoplasm Unresectable Pancreatic Adenocarcinoma

Start date: 2022-10-05
Primary completion: 2028-07-17
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.